• Je něco špatně v tomto záznamu ?

T-cell receptor antibodies expression in benign and malignant cutaneous lymphoid infiltrates in comparison with T-cell receptor gene rearrangement and its diagnostic utility in borderline cases

K. Kamarádová, K. Hrochová, M. Salavec, D. Belada

. 2020 ; 216 (12) : 153279. [pub] 20201104

Jazyk angličtina Země Německo

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026391

INTRODUCTION: Cutaneous T-cell lymphoid infiltrate can represent reactive lesion or a malignant T-cell lymphoma. However, clinical and histopathological appearance can overlap in both groups with a risk of misdiagnosis. Aberrant expression of T-cell markers is not always applicable and T-cell receptor (TCR) gene rearrangement is not always accessible and diagnosis in borderline cases can be challenging. AIMS: Several types of TCR antibodies are currently available with limited knowledge of their expression in different cutaneous lymphoid infiltrates. Aim of the study is a comparison of expression of TCR antibodies in benign and malignant lymphoid infiltrates and their utility in borderline cases. METHODS: Representative cases of reactive and malignant lymphoproliferations were collected. Separate group of lesions with borderline morphology was selected for comparison. Immunohistochemical expression of TCR-V-betaF1 (TCRBF1), TCR-C-beta1 (TCRJOVI.1), TCR gamma/delta (TCRGD) and TCR delta (TCRD) was performed in all cases. TCR gene rearrangement evaluation was performed in all cases using PCR BIOMED-2 assay. RESULTS: Benign lymphoid infiltrates were all negative in TCRD and TCRGD. Expression of TCRJOVI.1 was seen in 3/10 cases and TCRBF1 in one. T-cell lymphomas were positive for TCRBF1 and TCRGD in 60% and 30% of cases respectively. TCR gene rearrangement was confirmed in 90% of lymphoma cases. All benign lesions were polyclonal. Morphologically borderline lesions showed expression of TCRBF1 in 6/10 cases and TCR gene rearrangement in 4/10 cases. Re-evaluation of the cases and clinical correlation led to the change of the diagnosis and confirmation of T-cell lymphoma in 4/10 cases. CONCLUSIONS: Expression of TCRBF1 and TCR-gene rearrangement was significantly associated with malignant infiltrates. TCRBF1 positivity in borderline cutaneous lymphoproliferations can raise the suspicion of malignancy but confirmation by TCR gene rearrangement and careful clinical correlation is still advisable.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026391
003      
CZ-PrNML
005      
20211026132934.0
007      
ta
008      
211013s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.prp.2020.153279 $2 doi
035    __
$a (PubMed)33186884
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Kamarádová, K $u The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Králové, Sokolská 581, Hradec Králové, 500 03, Czech Republic. Electronic address: katerina.kamaradova@fnhk.cz
245    10
$a T-cell receptor antibodies expression in benign and malignant cutaneous lymphoid infiltrates in comparison with T-cell receptor gene rearrangement and its diagnostic utility in borderline cases / $c K. Kamarádová, K. Hrochová, M. Salavec, D. Belada
520    9_
$a INTRODUCTION: Cutaneous T-cell lymphoid infiltrate can represent reactive lesion or a malignant T-cell lymphoma. However, clinical and histopathological appearance can overlap in both groups with a risk of misdiagnosis. Aberrant expression of T-cell markers is not always applicable and T-cell receptor (TCR) gene rearrangement is not always accessible and diagnosis in borderline cases can be challenging. AIMS: Several types of TCR antibodies are currently available with limited knowledge of their expression in different cutaneous lymphoid infiltrates. Aim of the study is a comparison of expression of TCR antibodies in benign and malignant lymphoid infiltrates and their utility in borderline cases. METHODS: Representative cases of reactive and malignant lymphoproliferations were collected. Separate group of lesions with borderline morphology was selected for comparison. Immunohistochemical expression of TCR-V-betaF1 (TCRBF1), TCR-C-beta1 (TCRJOVI.1), TCR gamma/delta (TCRGD) and TCR delta (TCRD) was performed in all cases. TCR gene rearrangement evaluation was performed in all cases using PCR BIOMED-2 assay. RESULTS: Benign lymphoid infiltrates were all negative in TCRD and TCRGD. Expression of TCRJOVI.1 was seen in 3/10 cases and TCRBF1 in one. T-cell lymphomas were positive for TCRBF1 and TCRGD in 60% and 30% of cases respectively. TCR gene rearrangement was confirmed in 90% of lymphoma cases. All benign lesions were polyclonal. Morphologically borderline lesions showed expression of TCRBF1 in 6/10 cases and TCR gene rearrangement in 4/10 cases. Re-evaluation of the cases and clinical correlation led to the change of the diagnosis and confirmation of T-cell lymphoma in 4/10 cases. CONCLUSIONS: Expression of TCRBF1 and TCR-gene rearrangement was significantly associated with malignant infiltrates. TCRBF1 positivity in borderline cutaneous lymphoproliferations can raise the suspicion of malignancy but confirmation by TCR gene rearrangement and careful clinical correlation is still advisable.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protilátky $x imunologie $7 D000906
650    _2
$a specificita protilátek $7 D000918
650    _2
$a antigeny CD7 $x analýza $7 D019011
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    12
$a genová přestavba T-lymfocytů $7 D015329
650    _2
$a lidé $7 D006801
650    12
$a imunohistochemie $7 D007150
650    _2
$a kožní T-buněčný lymfom $x genetika $x imunologie $x patologie $7 D016410
650    _2
$a lymfoproliferativní nemoci $x genetika $x imunologie $x patologie $7 D008232
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a receptory antigenů T-buněk alfa-beta $x analýza $x genetika $7 D016693
650    _2
$a receptory antigenů T-buněk gama-delta $x analýza $x genetika $7 D016692
650    _2
$a kůže $x imunologie $x metabolismus $7 D012867
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hrochová, K $u Department of Clinical Biochemistry and Diagnostics, Charles University Faculty of Medicine and University Hospital Hradec Králové, Sokolská 581, Hradec Králové, 500 03, Czech Republic. Electronic address: katerina.hrochova@fnhk.cz
700    1_
$a Salavec, M $u Department of Dermatology and Venereology, Charles University Faculty of Medicine and University Hospital Hradec Králové, Sokolská 581, Hradec Králové, 500 03, Czech Republic. Electronic address: miloslav.salavec@fnhk.cz
700    1_
$a Belada, D $u 4thDepartment of Internal Medicine - Hematology, Charles University Faculty of Medicine and University Hospital Hradec Králové, Sokolská 581, Hradec Králové, 500 03, Czech Republic. Electronic address: david.belada@fnhk.cz
773    0_
$w MED00003712 $t Pathology, research and practice $x 1618-0631 $g Roč. 216, č. 12 (2020), s. 153279
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33186884 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132940 $b ABA008
999    __
$a ok $b bmc $g 1715188 $s 1146898
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 216 $c 12 $d 153279 $e 20201104 $i 1618-0631 $m Pathology, research and practice $n Pathol Res Pract $x MED00003712
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace